2014, Number 3
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2014; 52 (3)
Response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia
Ibarra-Hernández A, Sosa-Quintero LS, Garcés-Ruiz OM, Aguilar-López LB, Rubio-Jurado B, Vega-Ruiza A
Language: Spanish
References: 12
Page: 266-269
PDF size: 93.66 Kb.
ABSTRACT
Background: Chronic myeloid leukemia represents 15 % of all the
leukemias in adults. With the introduction of tyrosine kinase inhibitors,
overall survival at 10 years is 80-90 %. The objective was
to describe the epidemiology, complete cytogenetic response and
major molecular response with tyrosine kinase inhibitors in patients
with chronic myeloid leukemia.
Methods: It was performed a descriptive cross-sectional study of
patients with chronic myeloid leukemia and Philadelphia chromosome-
positive in treatment with tyrosine kinase inhibitors.
Results: The sample included 54 patients with a mean age of
41 years; 78 % of patients were in chronic phase, and in 8 %
of patients were identifi ed complex karyotype at diagnosis.
All patients received imatinib as fi rst-line treatment. We identifi
ed mutations in 8 %. The patients with primary or secondary
resistance (30%) received second-generation tyrosine kinase
inhibitors as a second-line therapy. Of 35 patients treated with
imatinib, 23 had complete cytogenetic response, 23 had major
molecular response, and 16 had loss of response to treatment. Of
nine patients treated with nilotinib, two presented complete cytogenetic
response, two major molecular response, and fi ve loss of
response to treatment. Of seven patients treated with dasatinib,
two had complete cytogenetic response, two major molecular
response, and four loss of response to treatment.
Conclusions: Of patients studied, 30 % was resistant to imatinib,
52 % achieved a complete cytogenetic response, and 42 % major
molecular response. The use of second generation tyrosine kinase
inhibitors led to obtain a complete cytogenetic and major molecular
response in fewer time.
REFERENCES
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic myelogenous leukemia. V. 3. Washington, USA: Nationa l Comprehensive Cancer Network; 2013.
Gómez-Almaguer D, Tarín-Arzaga LC. Tratamiento de la leucemia mieloide crónica en fase crónica: una perspectiva mexicana. Rev Hematol Mex. 2011;12 (4):267-75.
O´Brian S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-51.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med. 2006;354(24):2531-41.
Verweij J, Judson I, van Oosterom A. STI571: A magic bullet? Eur J Cancer. 2001;37(5):1816-9.
7 Carella A, Beltrami G, Corsetti MT. Autografting in chronic myeloid leukemia. Sem Hematol. 2003;40 (1):72-8.
Deininger MW, O’Brien SG, Ford JM. Practical management of patients with chronic myeloid. Leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637-47.
Cortés J, Giles F, O’Brien S, Thomas D, García- Manero G, Ríos MB, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome- positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102(1):83-6.
Marín D, Goldman JM, Olavarría E, Apperley JF. Transient benefi t only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102(7):2702-03.
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression- free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9);2096-102.
Kantarjian HM, Guilhot F, O’Brien SG, Mone M, Rudoltz M, Larson RA, et al. Effi cacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115(3):551-60.
Full text